174 related articles for article (PubMed ID: 12548355)
1. Amantadine in Huntington's disease: open-label video-blinded study.
Lucetti C; Gambaccini G; Bernardini S; Dell'Agnello G; Petrozzi L; Rossi G; Bonuccelli U
Neurol Sci; 2002 Sep; 23 Suppl 2():S83-4. PubMed ID: 12548355
[TBL] [Abstract][Full Text] [Related]
2. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
Mov Disord; 1998 Sep; 13(5):798-802. PubMed ID: 9756148
[TBL] [Abstract][Full Text] [Related]
3. Amantadine in the akinetic-rigid variant of Huntington's disease.
Magnet MK; Bonelli RM; Kapfhammer HP
Ann Pharmacother; 2004; 38(7-8):1194-6. PubMed ID: 15178736
[TBL] [Abstract][Full Text] [Related]
4. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
[TBL] [Abstract][Full Text] [Related]
5. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Verhagen Metman L; Morris MJ; Farmer C; Gillespie M; Mosby K; Wuu J; Chase TN
Neurology; 2002 Sep; 59(5):694-9. PubMed ID: 12221159
[TBL] [Abstract][Full Text] [Related]
6. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study.
Lucetti C; Del Dotto P; Gambaccini G; Dell' Agnello G; Bernardini S; Rossi G; Murri L; Bonuccelli U
Neurology; 2003 Jun; 60(12):1995-7. PubMed ID: 12821751
[TBL] [Abstract][Full Text] [Related]
7. Short-term variability in amplitude and motor topography of whole-body involuntary movements in Parkinson's disease dyskinesias and in Huntington's chorea.
Fenney A; Jog MS; Duval C
Clin Neurol Neurosurg; 2008 Feb; 110(2):160-7. PubMed ID: 18063471
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia.
Perez-Lloret S; Rascol O
J Neural Transm (Vienna); 2018 Aug; 125(8):1237-1250. PubMed ID: 29511826
[TBL] [Abstract][Full Text] [Related]
9. Drug treatments of levodopa-induced dyskinesias.
Vale S
Lancet; 1999 Aug; 354(9177):511. PubMed ID: 10465195
[No Abstract] [Full Text] [Related]
10. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Furukawa Y; Filiano JJ; Kish SJ
Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
[TBL] [Abstract][Full Text] [Related]
11. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial of amantadine in Huntington disease.
O'Suilleabhain P; Dewey RB
Arch Neurol; 2003 Jul; 60(7):996-8. PubMed ID: 12873857
[TBL] [Abstract][Full Text] [Related]
13. [A new treatment of Huntington's chorea. Report of three cases (author's transl)].
Zenglein JP; Baldauf E; Hussaini M
Sem Hop; 1978 Sep 18-25; 54(25-28):871-4. PubMed ID: 214869
[TBL] [Abstract][Full Text] [Related]
14. Glutamate-based therapeutic approaches: NR2B receptor antagonists.
Gogas KR
Curr Opin Pharmacol; 2006 Feb; 6(1):68-74. PubMed ID: 16376149
[TBL] [Abstract][Full Text] [Related]
15. Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Shen W; Ren W; Zhai S; Yang B; Vanoye CG; Mitra A; George AL; Surmeier DJ
J Clin Invest; 2020 May; 130(5):2593-2601. PubMed ID: 32310223
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.
Brigham EF; Johnston TH; Brown C; Holt JDS; Fox SH; Hill MP; Howson PA; Brotchie JM; Nguyen JT
J Pharmacol Exp Ther; 2018 Nov; 367(2):373-381. PubMed ID: 30087157
[TBL] [Abstract][Full Text] [Related]
17. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
[TBL] [Abstract][Full Text] [Related]
18. [Haloperidol, reserpine, l-dopa and amantidine in the treatment of Huntington chorea (author's transl)].
Candelise L
Riv Patol Nerv Ment; 1976; 96(1):54-62. PubMed ID: 134449
[TBL] [Abstract][Full Text] [Related]
19. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
20. Opposite effects of the A2A receptor agonist CGS21680 in the striatum of Huntington's disease versus wild-type mice.
Martire A; Calamandrei G; Felici F; Scattoni ML; Lastoria G; Domenici MR; Tebano MT; Popoli P
Neurosci Lett; 2007 Apr; 417(1):78-83. PubMed ID: 17331645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
